

Special Issue

MMPs and EMMPRIN/CD147 in Physiological and Pathological Processes 2.0

Message from the Guest Editor

MMPs have been implicated in numerous physiological and pathological situations, such as neoplasia, osteogenesis, myocardial infarction, osteoarthritis, or inflammation. Wide-ranging evidence has also implicated MMP dysregulation in tumor invasion, neoangiogenesis, and metastasis. EMMPRIN, a membrane glycoprotein greatly enriched on the surface of tumor cells, has been shown to stimulate the synthesis of MMPs in stromal cells and may account for the increased MMP expression in most cancer tissues. Apart from direct cell contact, cell interactions can also be influenced by soluble factors such as cytokines, growth factors, or extracellular vesicles. Such nodes of communication between cells might lead to dysregulations of ECM remodeling in physiological and pathological processes. In this Special Issue, original and review articles on basic science and preclinical and clinical findings are warmly welcome to contribute to our understanding of MMPs and their regulations.

Guest Editor

Dr. Eric Huet

TRePCa—Therapeutic Resistance in Prostate Cancer, Université Paris-Est Créteil, 94010 Créteil, France

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/127947

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).